Song Li
Founder & Executive ChairmanDr. Song Li, M.D., Ph. D., serves as FIAAM Interim CSO & Executive Director of SirnaMed Therapeutics Inc. Dr. Li had been Senior Vice President of CMC & Biological Analysis Business Line since February 22, 2017 at Hangzhou Tigermed Consulting Co., Ltd. and has been its Chief Executive Officer of US Frontage Laboratories Inc. since February 22, 2017. Dr. Li is a Founder and serves as Executive Chairman of the Board at Frontage Holdings Corporation since February 10, 2021 and served Chief Executive Officer at Frontage Holdings Corporation since February 10, 2021 until January 3, 2023. Prior to joining Frontage Holdings Group, Dr. Song Li held management positions at Great Valley Pharmaceuticals and Wyeth. Dr. Li served as the Honorary Chairman of the Frontage Holdings Corp. until February 10, 2021. During that period of time, he led numerous projects related to the development of pharmaceutical products. He served as President of Frontage Laboratories, Inc. Dr. Li served as Senior Vice President and Chief Executive Officer of Biological Analysis Business Line - Frontage Laboratories, Inc. since January 18, 2017 until February 22, 2017. Dr. Li served as the Chief Executive Officer of U. S. Fonda Medical Technology Co. Ltd. since January 5, 2017 until January 18, 2017. Dr. Li founded Frontage Laboratories, Inc. in 2001 has been responsible for leading its strategic, technical and commercial success. He also serves as Chairman of Board at Frontage Laboratories, Inc. Dr. Li served as the Chief Executive Officer and President of Frontage Laboratories, Inc. until January 5, 2017. Dr. Li served as Chief Executive Officer and President of Frontage Inc. He served as Chief Scientific Officer of Frontage Laboratories, Inc. He has pharmaceutical industry experience and also has expertise in analytical chemistry, method development, validation and regulatory affairs. Dr. Li leads numerous technical projects relating to the development of pharmaceutical products. He served in senior level management positions at Wyeth-Ayerst, Great Valley Pharmaceuticals and S. L. Pharma Labs, Inc. Dr. Li was formerly a Director in the second session and the third session of the Board of Directors of Hangzhou Tigermed from August 2014 to April 2018. Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics and analytical chemistry. Dr. Li served as Non-Independent Director at Hangzhou Tigermed Consulting Co., Ltd. since June 13, 2017. He has more than twenty scientific publications covering topics in chiral separations, drug-protein binding, pharmacokinetics and analytical chemistry. Dr. Li has been the recipient of numerous awards, most recently the Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, the Ernst & Young Entrepreneur of the Year Award, the “Realizing the American Dream” award from the Pennsylvania Welcoming Society and the Outstanding 50 Asian Americans in Business Award from the Asian American Business Development Center. Dr. Li received his Ph. D. in Analytical Chemistry from McGill University, Canada in 1992 and a Bachelor of Science in chemistry from Zhengzhou University, China and Post-doctoral Research in Pharmacokinetics at the Oncology Department from McGill University.
Positions
- Company NameFrontage Holdings CorporationStock Code01521PositionFounder & Executive ChairmanColleagues
- ZLZhongping LinCo-CEO Executive & Director
- WZWentao ZhangCo-CEO & Executive Director
- AEAbdul Ezaz MutlibChief Scientific & Strategy Officer and President of Frontage Laboratories of Canada
- HWHuan WangInterim Chief Financial Officer
- YLYifan LiIndependent Non Executive Director
- JWJingsong WangIndependent Non-Executive Director
